Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
YAC Biopharma
Wuhan, Hubei, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead candidate M701 (EpCAM x CD3 bispecific antibody) has pivotal/Phase III trial ongoing for malignant ascites with BLA submission expected Q1 2025. Multiple other bispecific antibodies in Phase I/II for oncology and ophthalmology indications.
- Therapeutic areas
- OncologyOphthalmologyInfectious Diseases
- Modalities
- Bispecific monoclonal antibodyRecombinant proteinVaccine
- Industry
- Biotech
02
Partnerships
CMS Vision (Y400 asset transfer)Wuhan Institute of Virology (Y2019)
Beyond the preview
Go deeper on YAC Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YAC Biopharma.